The secreted glycoprotein YKL-40 is a member of the chitinase family and elevated serum YKL-40 levels have been reported to be associated with reduced survival in several malignancies, including endometrial cancer. This study investigated immunoreactivity to YKL-40 protein and its prognostic implications in endometrial cancer. Levels of YKL-40 protein in normal endometrium (n = 42), endometrial hyperplasia (n = 40) and endometrial adeno carcinoma (n = 68) were examined using immunohistochemistry. YKL-40 immunoreactivity was significantly higher in endometrial adenocarcinoma compared with hyperplastic and normal endo metrium. In addition, high immuno reactivity of YKL-40 protein was associated with advanced stage, high histological grade, lymph node metastasis and lympho vascular invasion. Moreover, positive immunoreactivity for YKL-40 was a significant predictor of poor prognosis, as measured by estimated progression-free survival and estimated overall survival, compared with negative immunoreactivity. In conclusion, high YKL-40 immuno reactivity in endometrial cancer may be associated with poor prognosis.
Introduction
Endometrial cancer is the most common cancer of the genital tract in women and was estimated to account for 40 100 new cases and 7470 deaths in 2008. 1 Although the majority of patients (70 -80%) present with early-stage disease and have a 5-year survival rate of approximately 80%, a significant number of patients present with recurrent or advanced disease and show a poor outcome. 2 Thus, it is extremely important to have a better understanding of the underlying molecular factors related to prognosis in order to plan effective therapeutic strategies for women with advanced and recurrent endometrial cancer. Besides established prognostic factors in endometrial cancer, such as lymphovascular invasion, depth of myometrial invasion, grade and lymph node metastasis, 3 biochemical or molecular markers have gained more attention because of their close relationship with the intrinsic biological behaviour of endometrial cancer. In fact, some studies have identified the biological and clinical significance of several molecular alterations involved in endometrial tumour onset and progression, such as p53 mutations, defects in DNA mismatch repair, and mutations of the PTEN, KRAS and C Peng, J Peng, L Jiang et al. YKL-40 and endometrial carcinoma β-catenin genes. 4 New factors, however, still need to be identified so as to develop novel therapies to treat endometrial cancer.
YKL-40 was first discovered as a 40 kDa protein secreted by the MG63 human osteosarcoma cell line. 5 It belongs to the chitinase protein family, but has no chitinase activity. 6 Since this family is highly phylogenetically conserved, not surprisingly YKL-40 may be similar to other family members in the role it plays in collagen synthesis and extracellular matrix remodelling as well as in mitogenesis. 7 Although the exact function of YKL-40 is unclear, the pattern of its expression indicates a role in pathological processes related to inflammation, extracellular tissue remodelling and hepatic fibrosis. 8 In addition, elevated serum levels of YKL-40 have been shown in many types of solid tumour including breast tumour, cervical adenocarcinoma, ovarian tumour, small cell lung cancer and metastatic melanoma, and invariably it is associated with the aggressive behaviour of tumour cells and poor prognosis. 9 -14 These lines of evidence suggest that this protein may play a fundamental role in the neoplastic process.
Although the serum level of YKL-40 protein is known to be a prevalent and important prognostic factor in breast 9 and ovarian cancers, 12 the relationship between YKL-40 protein levels and clinical outcome in female cancers is inconsistent as some evidence shows a correlation between increased protein levels of YKL-40 and decreased disease-free survival, whereas other research does not. 11, 12, 15, 16 These contradictory data have prompted investigation of the possible value of YKL-40 in endometrial cancer. Moreover, since endometrial cancer shares histological subtypes and common risk factors with ovarian and breast cancer, these pathological similarities suggest that YKL-40 may have a potential role in endometrial cancer. In fact, it has been shown that a high serum level of YKL-40 has a diagnostic and prognostic role in endometrial cancer, 17 however, to our knowledge YKL-40 protein levels in endometrial tumourigenesis have never been investigated. Thus, the present study investigated the hypothesis that YKL-40 protein levels in endometrial tissue, like YKL-40 protein levels in serum, might be associated with prognosis in patients with endometrial cancer. To test this hypothesis, immunohistochemistry was used to investigate the levels of YKL-40 protein in atrophic, proliferative and secretory endometrium and in various types of endometrial hyperplasia, including simple hyperplasia and complex hyperplasia, and in endometrial adenocarcinoma.
In addition, the correlations between YKL-40 protein levels and various observed clinicopathological features and outcome in endometrial cancer patients were analysed.
Patients and methods

PATIENTS AND TISSUE SAMPLES
Archived formalin-fixed, paraffin-embedded samples were obtained from patients with hysteromyoma (atrophic, proliferative and secretory endometrium), endometrial hyperplasia (simple hyperplasia and complex hyperplasia) and endometrial adenocarcinoma who underwent surgery at the Tumour Hospital of Harbin Medical University, Harbin, China, between 2000 and 2004 and who had adequate tissue available for immunohistochemical evaluation. None of the patients had undergone neoadjuvant chemotherapy before surgery. Patients with endometrial adenocarcinoma were graded and staged according to criteria of the International Federation of Gynecology and C Peng, J Peng, L Jiang et al.
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Obstetrics (FIGO). 18, 19 Progression-free survival (PFS) and overall survival (OS) times were defined as the interval between the initial surgery and either clinically-or radiologically-proven recurrence and death, respectively. The study was approved by the Medical Ethics Committee of Harbin Medical University, China. Written informed consent was obtained from all patients.
IMMUNOHISTOCHEMISTRY AND SCORING OF IMMUNOSTAINED SPECIMENS
Immunohistochemistry was performed as follows. Endometrial tissue sections were dewaxed and rehydrated in a descending series of ethanol to water. The slides were incubated in 3% hydrogen peroxide for 15 min to quench endogenous peroxidase activity. For antigen retrieval, the slides were placed in 0.01 M citrate buffer, pH 6.0, and heated in a steamer for 30 min. The sections were incubated overnight at 4°C with primary antibody against YKL-40 (1:200 dilution, Cat. No. 4815; Quidel, Santa Clara, CA, USA). They were then rinsed with 50 mM Tris-buffered saline (TBS, pH 7.4) before being incubated with secondary antirabbit immunoglobulin G-polymer horseradish peroxidise (HRP) antibody (Polink-2 Rb DAB kit, Cat. No. D 39-6; Golden Bridge International, Mukilteo, WA, USA) for 45 min at 37°C, before finally being rinsed with TBS. For colour development, the sections were incubated with 3,3′-diaminobenzidine tetrachloride (DAB ZLI-9034; ZhongShan Biological Technology, Beijing, China) for 5 -10 s and counterstained with haematoxylin and eosin. As a negative control, the primary antibody was omitted. A glioblastoma multiforme was used as the positive control for YKL-40 staining.
Immunoreactivity to YKL-40 was recognized as brown staining within cells.
For the evaluation of YKL-40 immunoreactivity, the staining intensity was scored as 0 (negative), 1 (weak), 2 (medium), or 3 (strong). The extent of staining was scored as 0 (0%), 1 (1 -10%), 2 (11 -50%), or 3 (51 -100%) according to the percentage of positively stained areas relative to the total tumour area. The sum of the scores for the intensity and extent of staining was used to calculate the final staining score (0 -6) for YKL-40. Tumours having a final staining score > 3 were considered to be positive for YKL-40 protein. The scoring procedure was carried out twice by two independent observers (each blinded to the other's score) without any knowledge of the clinical parameters or other prognostic factors. The concordance rate was over 95% between the two observers.
WESTERN BLOT ANALYSIS
Frozen tissues were homogenized in modified radioimmunoprecipitation assay buffer (Biyuntian, Shanghai, China) supplemented with 1 mM phenylmethylsulphonyl fluoride. Each sample was mixed with an equal volume of 2 × loading buffer, boiled, subjected to 10% sodium dodecyl sulphatepolyacrylamide gel electrophoresis and transferred to nitrocellulose membranes by semi-dry electrophoresis. The membranes were incubated in blocking solution ( 
STATISTICAL ANALYSIS
All statistical analyses were carried out using the SPSS ® statistical package, version 13.0 (SPSS Inc., Chicago, IL, USA) for Windows ® . The χ 2 -test was used to analyse the distribution of YKL-40-positive cases according to clinicopathological parameters. Survival analyses were conducted according to the Kaplan-Meier methods. Comparison of the survival between groups was performed with the log rank test. A P-value < 0.05 was considered to be statistically significant.
Results
PATIENTS AND TISSUE SAMPLES
In total, 150 patients were selected to provide samples comprising 42 normal endometria (10 atrophic endometria; 16 proliferative endometria; 16 secretory endometria), 40 endometrial hyperplasia (20 simple hyperplasia; 20 complex hyperplasia), and 68 endometrial adenocarcinomas. The mean age of the patients with endometrial adenocarcinoma was 52 years (range 29 -68 years) and they were staged according to FIGO criteria: 18, 19 40 were stage I (four were IA, 26 were IB, 10 were IC); nine were stage II; 16 were stage III; and three were stage IV. Histological grade of endometrial adenocarcinoma was: 34 were G1 (well differentiated); 18 were G2 (moderately differentiated); and 16 were G3 (poorly differentiated).
YKL-40 IN ENDOMETRIAL ADENOCARCINOMA AND ITS PRECURSOR LESIONS
Immunoreactivity to YKL-40 protein was recognized as brown staining within cells and, as shown in Fig. 1A , was localized in the cytoplasm of tumour and normal cells but not in the stroma. Endometrial cancer showed the strongest immunoreactivity for YKL-40 compared with endometrial hyperplasia and normal endometrium ( Fig.  1B ; χ 2 -test, P < 0.05). This immunohistochemical staining pattern was confirmed by Western blot analysis (Fig. 1C) . Categorization of YKL-40 immunoreactivity into negative versus positive revealed that the presence of YKL-40 was associated with the following clinicopathological parameters: advanced FIGO stage (P = 0.038); high FIGO grade (P = 0.046); lymphovascular invasion (P = 0.014) and lymph node metastasis (P = 0.027) ( Table 1) .
CORRELATION OF YKL-40 LEVELS WITH PATIENT SURVIVAL
The PFS and OS curves of the 68 patients with endometrial adenocarcinoma stratified according to their YKL-40 status are shown in Fig. 2 . Patients exhibiting positive YKL-40 immunoreactivity had significantly lower PFS and OS rates than those of patients exhibiting negative YKL-40 immuno reactivity (P = 0.008 and P = 0.011, respectively). Univariate analyses in terms of survival in relation to the various clinicopathological variables are shown in Table 2 .
Discussion
To our knowledge, the present study is the first to demonstrate YKL-40 immunoreactivity in normal, hyperplastic and carcinomatous endometria. It was found that YKL-40 protein was located in the cytoplasm, which was consistent with similar studies of breast cancers 15 and glioblastomas. 20 Meanwhile, high YKL-40 immunoreactivity was observed in endometrial adenocarcinomas compared with weak or negative immunoreactivity in the majority of hyperplastic as well as The present study adds to the growing evidence that YKL-40 may play an important role in the progression of malignancies. As a secreted glycoprotein, the complete biological function of YKL-40 in vivo has not yet been identified, although some in vitro research has demonstrated that YKL-40 may play a positive role in regulating cell growth, migration and invasion. 21 -23 Meanwhile immortalized human astrocytes stably transfected with CHI3L1/YKL-40 acquired radioresistance and increased invasive capacity in vitro compared with parental cells. 24 In addition, YKL-40 overexpression is YKL-40 was identified as an independent prognostic factor for survival in patients with ovarian cancer. 11, 12 In the present patient C Peng, J Peng, L Jiang et al. YKL-40 and endometrial carcinoma cohort, tumours that were highly immunoreactive for YKL-40 were associated with several aggressive clinical variables, including advanced stage, poor differentiation, lymph node metastasis and lymphovascular invasion, and were also significantly associated with poor prognosis in endometrial cancer. In agreement with these data, Diefenbach et al. 17 also reported that serum levels of YKL-40 in endometrial cancer play a prognostic role. The presence of YKL-40 protein in endometrial cancer seems, therefore, to be associated with aggressive biological characteristics and may play an important role in prognosis and/or recurrence, although the mechanisms involved in cancer aggressiveness are only poorly understood at present.
It has been suggested that YKL-40 could stimulate migration of endothelial cells and modulate vascular endothelial cell morphology by promoting the formation of branching tubules. 22, 23 Thus, YKL-40 may potentially be involved in angiogenesis surrounding the tumour and play a role in the growth of primary and metastatic tumours, which was further clarified in vivo by Shao et al. 26 These findings may help to shed light in future studies on the angiogenic signature of YKL-40 in a wide range of human cancers. Additionally, YKL-40 has been shown to be up-regulated by genotoxic stress in human glioblastoma cell lines, which indicates that YKL-40 may act as a cell survival factor in adverse microenvironments. 27 Moreover, YKL-40 can stimulate the growth of fibroblast cell lines and modulate collagen formation as well as bind to hyaluronan, 21, 28, 29 so it could be involved in interactions between tumour cells and their environment and, subsequently, influence the stroma around primary tumours and metastatic sites to facilitate the malignant invasive process. As neoplasms are biologically heterogeneous and contain subpopulations of cancer cells with different angiogenic, invasive and metastatic properties, YKL-40positive cancer cells may have a different phenotype compared with YKL-40-negative cancer cells; therefore, YKL-40 may reflect differences in the biology of various cancer The present study differed from the previous study of serum YKL-40 in endometrial carcinoma carried out by Diefenbach et al. 17 who reported no significant correlation between high serum YKL-40 levels and clinicopathological features, such as tumour grade or stage. They frequently detected elevated levels of serum YKL-40 in patients with advanced clinical stage compared with early-stage patients, but this difference did not attain statistical significance, possibly because of their relatively small sample size. 17 Currently, the relationship between tissue level and serum concentration of YKL-40 in the same cancer patients remains unclear because relevant research is limited. 12, 30 Further studies are required to resolve this issue in endometrial cancer.
In conclusion, YKL-40 protein levels, as determined by immunohistochemistry, might help to identify patients with a poor prognosis in endometrial cancer. Due to the relatively small cohort size of this and other studies, additional larger, prospective studies of YKL-40, focusing on protein levels in both the serum and tissue from the same endometrial cancer patients, are needed to give a better evaluation of this potential diagnostic and prognostic marker.
